Who Exports Levamisole from India — 72 Suppliers Behind a $2.7M Market
India's levamisole export market is supplied by 72 active exporters who collectively shipped $2.7M across 325 shipments. LYKA BDR INTERNATIONAL LIMITED leads with a 24.7% market share, followed by LYKA LABS LIMITED and COMBITIC GLOBAL CAPLET PRIVATE LIMITED. The top 5 suppliers together control 66.2% of total export value, reflecting a concentrated market structure.
Top Levamisole Exporters from India — Ranked by Export Value
LYKA BDR INTERNATIONAL LIMITED is the leading levamisole exporter from India, holding a 24.7% share of the $2.7M market across 325 shipments from 72 exporters. The top 5 suppliers — LYKA BDR INTERNATIONAL LIMITED, LYKA LABS LIMITED, COMBITIC GLOBAL CAPLET PRIVATE LIMITED, DOSCH PHARMACEUTICALS PRIVATE LIMITED, PRASHI PHARMA PRIVATE LIMITED — collectively control 66.2% of total export value, indicating a moderately concentrated market. Individual shares are: LYKA BDR INTERNATIONAL LIMITED (24.7%), LYKA LABS LIMITED (14.6%), COMBITIC GLOBAL CAPLET PRIVATE LIMITED (13.8%), DOSCH PHARMACEUTICALS PRIVATE LIMITED (6.9%), PRASHI PHARMA PRIVATE LIMITED (6.1%).
Top Levamisole Exporters from India
Ranked by export value · 72 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LYKA BDR INTERNATIONAL LIMITED FASMIN DS SUSPENSION 1 LTR (LEVAMISOLE HFASMIN DS SUSPENSION 1 LTR LEVAMISOLE HFASMIN DS SUSPENSION 1 LTR 3% W/V OXYCLOZANIDE BP =6%W/V | $658.4K | 2 | 24.7% |
| 2 | LYKA LABS LIMITED FASMIN DS SUSPENSION 1 LTR (LEVAMISOLE HFASMIN DS SUSPENSION 1 LTR LEVAMISOLE HFASMIN DS SUSPENSION 1 LTR 3% W/V OXYCLOZANIDE BP =6%W/V | $387.4K | 1 | 14.6% |
| 3 | COMBITIC GLOBAL CAPLET PRIVATE LIMITED ALBENDAZOLE & LEVAMISOLE TABLET GLISTAGALBENDAZOLE & LEVAMISOLE TABLET (GLISTAGLEVAMISOLETABLET IP 150MG ( KETRAX-150TA | $367.2K | 2 | 13.8% |
| 4 | DOSCH PHARMACEUTICALS PRIVATE LIMITED LEVAMISOLE HYDROCHLORIDE TABLETS 150 MGLEVAMISOLE HCL TABLETS 150 MGHARMLESS MEDICINES, LEVAMISOLE HCL TABLE | $184.9K | 2 | 6.9% |
| 5 | PRASHI PHARMA PRIVATE LIMITED LEVAMISOLE HYDROCHLORIDE TABLETS 150 MGLEVAMISOLE HCL TABLETS 150 MGHARMLESS MEDICINES, LEVAMISOLE HCL TABLE | $163.3K | 2 | 6.1% |
| 6 | DIPS BIOSCIENCE PRIVATE LIMITED VAMISOL 1000 LEVAMISOLE HCL BP 1000MGVAMISOL 300 LEVAMISOLE HCL BP 300MG 20 | $95.5K | 1 | 3.6% |
| 7 | ASHISH LIFE SCIENCE PRIVATE LIMITED ANIMAL FEED SUPPLEMENT - LEVAMISOLE-300 AS PER INVOICEANIMAL FEED SUPPLEMENT - LEVAMISOLE-1000 AS PER INVOICE | $93.6K | 5 | 3.5% |
| 8 | FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED ALBENDAZOLE & LEVAMISOLE TABLET GLISTAGALBENDAZOLE & LEVAMISOLE TABLET (GLISTAG | $75.0K | 2 | 2.8% |
| 9 | AMBADNYA LIFE SCIENCE LLP LEVAMISOLE HYDROCHLORIDE TABLETS 150 MGLEVAMISOLE HCL TABLETS 150 MGHARMLESS MEDICINES, LEVAMISOLE HCL TABLE | $58.8K | 1 | 2.2% |
| 10 | SHREE PHARMA INDIA | $50.2K | 1 | 1.9% |
| 11 | INDIAN GENOMIX PRIVATE LIMITED LEVAMISOLETABLET IP 150MG ( KETRAX-150TALEVAMISOLE 30 REST DETAILS AS PER DOCUMENTLEVAMISOLE 15% 5GM OTHER DETAILS AS PER | $49.8K | 3 | 1.9% |
| 12 | SKM PHARMA PRIVATE LIMITED, | $30.9K | 1 | 1.2% |
| 13 | SHREE PHARMA (INDIA) | $30.2K | 1 | 1.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Levamisole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| LYKA LABS LIMITED | Not Listed | Yes, as of March 16, | No | Not verified | WHO-GMP certification valid until March 16, 2024, for sterile powder for injecti |
| FLAGSHIP BIOTECH INTERNATIONAL PRIVATE LIMITED | Not Listed | Yes, as of September | No | Not verified | WHO-GMP certification valid until September 11, 2025, for parenteral (LVP) in pl |
| COMBITIC GLOBAL CAPLET PRIVATE LIMITED | Not Listed | No | No | Not verified | Blacklisted by the Pharmaceuticals & Medical Devices Bureau of India in December |
TransData Nexus reviewed the regulatory standing of 3 leading Levamisole exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 0 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Levamisole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including major players like Dr. Reddy’s Laboratories and Aurobindo Pharma. This concentration of API manufacturers makes Hyderabad a critical hub for sourcing bulk drugs such as Levamisole.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a significant center for pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses companies like Zydus Cadila and Torrent Pharmaceuticals. The region's robust infrastructure and regulatory compliance make it a preferred location for the production of finished dosage forms, including Levamisole tablets.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceuticals. Mumbai, being a major port city, facilitates the export of pharmaceutical products to various international markets. The region is home to numerous pharmaceutical companies and trading houses that specialize in the export of APIs and finished formulations, including Levamisole.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, has emerged as a prominent pharmaceutical manufacturing hub, largely due to favorable tax incentives and government policies. The region hosts over 1,000 pharmaceutical manufacturing units, making it one of the largest pharmaceutical clusters in Asia. Companies in Baddi produce a wide range of pharmaceutical products, including Levamisole, benefiting from cost-effective manufacturing and proximity to key markets.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of suppliers in Hyderabad for APIs and in Ahmedabad-Vadodara for formulations.
- Leverage Export Hubs: Utilize the Mumbai-Thane-Raigad region for efficient export logistics and access to international markets.
- Consider Cost Advantages: Explore sourcing from Baddi-Nalagarh to benefit from cost-effective manufacturing due to tax incentives and established infrastructure.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Levamisole exporters from India
Lyka Labs Limited — Lyka Labs receives CDSCO approval for Tofacitinib Ointment
Lyka Labs Limited obtained permission from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Tofacitinib Ointment 2% w/w after completing clinical trials on 125 patients across eight centers in India. - IMPACT: This approval may enhance Lyka Labs' product portfolio, potentially influencing their Levamisole export operations.
Impact: This approval may enhance Lyka Labs' product portfolio, potentially influencing their Levamisole export operations.
Lyka Labs Limited — Lyka Labs plans 50% lyophilisation capacity increase
Lyka Labs announced plans to upgrade and expand its lyophilisation capacity by 50%, aiming to complete the project in the financial year 2026 to support entry into regulated markets such as Europe and the UK. - IMPACT: The expansion could bolster production capabilities, potentially affecting Levamisole export volumes.
Impact: The expansion could bolster production capabilities, potentially affecting Levamisole export volumes.
Lyka Labs Limited — Lyka Labs introduces FertiNova division for ART solutions
Lyka Labs ventured into Gynaecology and Assisted Reproductive Technology (ART) through its new division, FertiNova, focusing on advanced IVF solutions and women's health therapies, targeting a strong market presence over the next three years. - IMPACT: Diversification into ART solutions may influence resource allocation, potentially impacting Levamisole export focus.
Impact: Diversification into ART solutions may influence resource allocation, potentially impacting Levamisole export focus.
Common Questions — Levamisole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which levamisole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LYKA BDR INTERNATIONAL LIMITED leads with 11 recorded shipments worth $658.4K. LYKA LABS LIMITED (3 shipments) and COMBITIC GLOBAL CAPLET PRIVATE LIMITED (25 shipments) are also established high-volume exporters.
Q How many levamisole manufacturers are there in India?
India has 72 active levamisole exporters with a combined export market of $2.7M across 325 shipments to 39 countries. The top 5 suppliers hold 66.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for levamisole from India?
Average FOB unit price: $7.36 per unit, ranging from $0.00 to $284.46. Average shipment value: $8.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 72 verified Indian exporters of Levamisole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 325 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 39 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
325 Verified Shipments
72 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists